Blueberries Medical Announces the launch of new markets for its products, partnerships in agronomic operation and the Extension of Maturity Date of Convertible Debenture

TORONTO, July 29, 2022 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CNSX:BBM.CN) (OTC:BBRRF) (FRA:1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, announces that has achieved several CBD and non-psychoactive derivatives shipments to customers in Argentina, and up to date has exported a total of more than 60 kg to 6 different buyers. Quality validation processes with larger pharmaceutical and cosmetics companies in this country are running positively, and the company estimates annual sales above $2.5 MM in 2023. It is also expected that in late Q3 2022, Blueberries initiates the delivery of multiple high THC formulations locally and internationally, starting with Brazil as the first country to export psychoactive formulations. Both Argentina and Brazil are then expected to become the two largest destinations of the company products in next quarters.